top of page
All posts
Alzheimer's
ANVISA
Author: Allan Matsui
Author: Jairo Utimi
Author: Claudia Cilento
Author: Nilva Bortoleto
BPF
Cannabidiol
Cancer
Cannabis
Coronavirus
Covid-19
challenges
Epilepsy
pharmaceutical
IFA
pharmaceutical industry
Inovatie
medicines
opportunities
Parkinson
pharmaceuticals
pharmaceutical industry
Author: Camille Rodrigues da Silva
Incremental innovation
Investments
Marketing
News
Incremental innovation
Good Manufacturing Practices
Search
Dec 22, 2021
Clinical research in Brazil – New horizons, new challenges
Feb 9, 2021
Unraveling the Abbreviated Development Path
Feb 9, 2021
COVID-19: What facilities is ANVISA providing at this time of crisis?
Feb 9, 2021
Why are 24% of drug registrations still rejected?
Feb 9, 2021
API, BPF and drug dossier - How to align the processes to ensure success in registration?
Feb 9, 2021
NEW API REGULATORY FRAMEWORK: Will ANVISA and international manufacturers be prepared?
Feb 9, 2021
Publication of the new API regulatory framework: what is essential to know?
E-BOOKS
CONTEÚDOS EXCLUSIVOS PARA AUXILIAR EM
SEU TRABALHO
Acesse
bottom of page
